Promising combo for tough leukemia hits roadblock: trial stopped early
NCT ID NCT04874194
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs, omacetaxine and venetoclax, in 24 adults with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that had a specific genetic change called RUNX1. The goal was to find the best dose and see if the combo could help control the disease. However, the study was terminated early, so we don't have full results on how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Omacetaxine and venetoclax
- What this could lead to
- If it had worked, this combination could have offered a new treatment option for people with hard-to-treat leukemia or MDS who have a specific genetic change (RUNX1 mutation).
- What could go wrong
- The trial was terminated early, so we don't have clear evidence that this combination works. It was also a small, early-phase study, so even if it had continued, success was not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer reveal hidden immune clues in tumors?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?
- Can a Two-Step stem cell transplant tame Graft-Versus-Host disease?
- Lab-Grown stem cells could speed immune recovery in blood cancer transplants
- New drug aims to wake up immune system against Hard-to-Treat leukemia